Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06183489 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT06183489 · ClinicalTrials.gov record · last posted 2024-10-18

Use of Elranatamab in Patients With High-risk Smoldering Multiple Myeloma

Study acronym: ERASMM
StatusRecruiting
PhasePhase 2
Started2024-05-14
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
This is a multicenter, single arm, open-label, Phase 2 study in high risk smoldering myeloma patients. The primary objective is to determine the efficacy of Elranatamab in patients with previously untreated high-risk SMM. The key-secondary objective is to determine the safety of Elranatamab in patients with previously untreated high-risk SMM.

Amendment record 7 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 7 times since 2023-12-14; most recent amendment 2024-10-16. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2024-05-15
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT06183489
Lead Sponsor Stichting European Myeloma Network
Collaborators: Pfizer
Conditions Smoldering Multiple Myeloma
Enrollment 50 participants
Start Date 2024-05-14
Primary Completion 2027-07 (estimated)
Study Completion 2031-07 (estimated)
Updated on ClinicalTrials.gov 2024-10-18